

4DMedical signs agreements with leading global pharmaceutical company, Royal Melbourne Hospital and Spectrum Medical Imaging

8 September 2025

Highlights

- In collaboration with a leading global pharmaceutical company, 4DMedical launches a lung health screening program in Brazil, focusing on lung cancer screening and detecting incidental findings like coronary artery calcification and COPD
- Royal Melbourne Hospital will pilot 4DMedical's full portfolio for advanced lung ventilation analysis and clinical imaging assessment of lung health
- 4DMedical and Spectrum Medical Imaging (NSW) enter a multi-year agreement to support the National Lung Cancer Screening Program in Australia

Melbourne, Australia, 8 September 2025 – 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a global leader in respiratory imaging technology, today announces agreements with a leading global pharmaceutical company, Royal Melbourne Hospital and Spectrum Medical Imaging to deploy its lung health analysis software. The agreements, spanning to 2027, aim to support lung cancer screening, including the recently commenced National Lung Cancer Screening Program (NLCSP) in Australia, and improve lung health assessment.

Collaboration with leading global pharmaceutical to support Brazilian lung health screening

Under an agreement with a leading global pharmaceutical company, 4DMedical has commenced rollout of Lung Health Screening in Brazil. The initial site for the program is Hospital Madre Teresa in Belo Horizonte, with a focus on lung cancer screening and the detection of incidental findings such as coronary artery calcification (CAC) and chronic obstructive pulmonary disease (COPD). This initial agreement covers analysis of up to 10,000 scans through to August 2026. The program seeks to provide national coverage across Brazil, following an initial phase of 8 hospitals.

Royal Melbourne Hospital to pilot 4DMedical's full portfolio

Royal Melbourne Hospital (Melbourne Health) has entered into a pilot agreement to deploy the full 4DMedical portfolio to support advanced lung ventilation analysis and clinical imaging assessment of lung health. This includes CT LVAS™, XV LVAS™, LDAi, LDAf, Lung Texture Analysis, and low-dose CT nodule detection as part of the NLCSP. The pilot, running to 31 December 2025, marks Royal Melbourne Hospital as the first Australian public hospital and Academic Medical Centre (AMC) to roll out the 4DMedical suite, further extending the reach of our technology into frontline clinical practice.



National Lung Cancer Screening included in expanded contract with Spectrum

4DMedical has entered into a multi-year agreement with Spectrum Medical Imaging (NSW) to support its Lung Health programs, including low-dose CT nodule detection in the NLCSP. Spectrum has been an emerging provider of CT LVAS™ to its referrers, and this contract broadens the technology stack to include low-dose CT nodule detection, and the structural suite of CT reports including LDAi, Lung Map for Smoking Cessation, Lung Texture Analysis, and LDAf. The agreement commences immediately and will run until 30 June 2027, with financial terms remaining commercial in confidence. Spectrum Medical Imaging co-founder and partner, Dr Glen Schlaphoff, provided the commentary below on the collaboration.

Transforming Lung Health: Spectrum & 4DMedical's Collaboration

At Spectrum Medical Imaging, our mission has always been to deliver the most accurate, efficient, and patient-centred diagnostic services. By partnering with 4DMedical, an industry leader in lung imaging analysis, we are redefining how lung diseases are detected, understood, and treated.

Advanced Analytical Lung Software: Deeper Insights from Imaging

Through 4DMedical's suite of Software-as-a-Service (SaaS) tools, Spectrum clinicians can access advanced lung function analytics using existing imaging hardware:

CT LVAS™ overlays functional data, such as ventilation patterns, over CT scan structures, providing a more complete picture of lung health using standard CT acquisitions.

Driving Impact through the National Lung Cancer Screening Program (NLCSP)

Since launching on 1 July 2025, Spectrum has been a proud provider within Australia's National Lung Cancer Screening Program (NLCSP), offering Medicare-funded low-dose CT scans to eligible populations. By integrating 4DMedical's analytical software into the NLCSP, Spectrum enhances the depth and quality of screening:

- Low-dose CT scans now yield both structural and functional insights, enabling earlier intervention and targeted referral pathways; and
- Quantitative data supports more accurate risk stratification for findings like emphysema or airflow impairment, fostering proactive patient management.

Advantages of Spectrum's Partnership with 4DMedical

- **Innovation at No Extra Equipment Cost:** Spectrum deploys 4DMedical's solutions using our existing imaging infrastructure, reducing barriers to adoption;
- **Global Validation, Local Application:** Backed by regulatory clearances, including FDA approval for both XV LVAS™ and CT LVAS™, 4DMedical's tools offer trusted, validated performance;
- **Broad Spectrum of Clinical Use Cases:** From early detection in lung cancer screening to monitoring COPD, fibrosis, and post-transplant outcomes, the tools support a wide range of clinical specialties; and
- **Joint Commitment to Quality Care:** Together, Spectrum and 4DMedical elevate respiratory diagnostics, offering precision, speed, and actionable insights that benefit clinicians and patients alike.



4DMedical is proud to work with Spectrum Medical Imaging and applaud their commitment to delivering high-quality care.

4DMedical MD/CEO and Founder Andreas Fouras said:

In parallel to our US efforts to bring CT:VQ™ to market, we are pleased to see progress on other products in the portfolio in countries where CT:VQ™ is yet to receive regulatory clearance.

4DMedical is committed to Australian healthcare, and is excited to support the National Lung Cancer Screening Program - this is a key piece of Australian healthcare infrastructure and we believe our suite of products can play a big role.

I am excited to have Royal Melbourne Hospital as the first Australian public hospital and Academic Medical Centre to roll out the 4DMedical suite, further extending the reach of our technology into frontline clinical practice.

Lastly, in Brazil, our partnership with a global pharmaceutical offers further evidence of the growth of our reputation and a real opportunity to expand our reach to millions in South America.

Since announcing FDA clearance for CT:VQ™, we've experienced a very real change in our interactions with healthcare providers. I look forward to providing shareholders with further updates as they become available.

—ENDS—

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com